Recurrent complement-mediated Hemolytic uremic syndrome after kidney transplantation

Area of Science:

• Nephrology
• Immunology
• Genetics

Background:

• Hereditary hemolytic uremic syndrome (HUS), now termed complement-mediated HUS (cHUS), arises from genetic defects in the complement alternative pathway.
• cHUS poses a high risk of recurrence in kidney transplant recipients, often leading to graft failure.
• The anti-complement C5 antibody, eculizumab, has revolutionized cHUS management, drastically lowering recurrence rates and enhancing graft survival.

Purpose of the Study:

• To review the pathophysiology, classification, and genetic basis of cHUS.
• To explore current and emerging management strategies for cHUS in both native and transplanted kidneys.
• To address critical questions regarding complement inhibitor discontinuation and patient selection for treatment withdrawal.

Main Methods:

• Comprehensive literature review of studies on cHUS, complement pathways, and eculizumab therapy.
• Analysis of genetic predispositions and their impact on cHUS pathophysiology.
• Evaluation of clinical outcomes in kidney transplant recipients with cHUS treated with eculizumab.

Main Results:

• Mutations in complement alternative pathway genes are central to cHUS development.
• Eculizumab therapy demonstrates significant efficacy in preventing cHUS recurrence post-transplantation.
• Optimal strategies for eculizumab discontinuation and genetic marker-guided patient selection require further investigation.

Conclusions:

• cHUS management has been transformed by complement inhibition, particularly eculizumab, improving transplant outcomes.
• Understanding genetic factors is crucial for personalized cHUS treatment and management.
• Further research is needed to define protocols for treatment cessation and long-term management of cHUS patients.